Eli Lillys $6.5B Texas manufacturing facility demonstrates the industrys urgent need for domestic ingredient production
When the dollar rate increases, manufacturing costs rise immediately
In November 2023, AstraZeneca and Eccogene signed an exclusive license agreement for ECC5004, an investigational oral once-daily GLP-1RA for treating obesity, type 2 diabetes, and other cardiometabolic conditions
Protein-forward meals, water, and GLP-1 supplement support, plus lower-fat foods during escalation, all help with tolerance
[2] Exceptions to the ban are phenylephrine and pseudoephedrine
[1] The CagriSema combination research dosage reference frames these figures as research-use-only